03:05:30 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-21 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-07-03 Ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2020-03-25 08:00:00

Drs. Mika Niemelä and Behnam Rezai Jahromi will lead efforts that initially focus on treatment of Intraventricular Hemorrhage

Stockholm, March 25, 2020 - IRRAS, a global medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced a long-term collaboration with Dr. Nika Niemela, Professor and Chairman of Neurosurgery, and Dr. Behnam Rezai Jahromi from the University of Helsinki, one of the world's leading neurosurgical institutions, to utilize the company's IRRAflow system in a variety of neurocritical applications.  The initial area of focus  will be  in the treatment of patients suffering from intraventricular hemorrhage (IVH).

IRRAflow is the world's first "irrigating intracranial drain," and its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid by using a dual-lumen catheter that combines automated irrigation, controlled drainage, and continuous ICP monitoring, all into one system.  IRRAflow was introduced into the U.S. market in 2019 following the receipt of 510(k) clearance by the United States Food and Drug Administration (FDA) and is currently being reintroduced into the European Union (EU) after the recertification of the system's CE Mark in December 2019. 

"It is my belief that the system's combination of automated irrigation and controlled drainage should contribute to better long-term outcomes for these critically ill patients, and I am excited to explore that hypothesis in greater detail," said Dr. Mika Niemelä. "My early experience with the IRRAflow system has shown impressive acute results in draining collected toxic material out of the ventricles without catheter blockages," said Dr. Rezai Jahromi.  "

Traditional treatment options for IVH patients generally utilize an external ventricular drainage (EVD) system, which is a passive approach that relies solely on gravity to facilitate drainage. Although an EVD is currently the most common treatment option for intracranial bleeding or elevated ICP, the technology is associated with several well-known complications such as catheter blockage, infections, and incomplete drainage.  All of these complications can negatively impact patient outcome, which can subsequently increase the length of time needed in the hospital and the overall cost of care.  

HUH Neurosurgery is world-famous for its expertise in all subsections of neurosurgery. It is considered the leading center in Europe in the microneurosurgical treatment of cerebral blood vessel diseases and complex brain tumors and is also ranked among the very best units in the world. Due to this reputation as one of the world's leading centers in cerebrovascular problems, some of the most complex cases in the field are referred to Helsinki from other parts of the world. Each year, more than 3,200 patients undergo neurosurgical treatment at Helsinki, and nearly 200 neurosurgeons from all around the world visit the facility to learn the latest techniques in neurosurgery. 

"This collaboration with Dr. Rezai Jahromi and the University of Helsinki represents an important component of our launch strategy for IRRAflow," said Will Martin, Chief Commercial Officer of IRRAS. "There is a compelling need for transformative technologies, such as IRRAflow, to treat patients with intracranial bleeding, and we believe that this collaboration will advance the treatment of IVH and also accelerate the product's awareness to a wider group of neurocritical care specialists."

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS AB (publ) is listed on Nasdaq First North Premier Growth Market (ticker: IRRAS). Redeye AB is certified adviser of the company with email, certifiedadviser@redeye.se, orphone +46 8 121 576 90. 

For more information, please contact:

USA
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
ir@irras.com  

Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com

 

The information was released for public disclosure, through the agency of the contact person above, on March 25, 2020 at 08:00 a.m. (CET).